Increased Expression of Autophagy Protein LC3 in Two Patients With Progressing Chronic Lymphocytic Leukemia.
LC3
autophagy
cancer
chronic lymphocytic leukemia
progressing
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2020
2020
Historique:
received:
29
05
2019
accepted:
27
04
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
11
5
2021
Statut:
epublish
Résumé
Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia in the western hemisphere. It is characterized by a clonal proliferation of a population of CD5+ B lymphocytes that accumulate in the secondary lymphoid tissues, bone marrow, and blood. Some CLL patients remain free of symptoms for decades, whereas others rapidly become symptomatic or develop high-risk disease. Studying autophagy, which may modulate key protein expression and cell survival, may be important to the search for novel prognostic factors and molecules. Here, we applied flow cytometry technology to simultaneously detect autophagy protein LC3B with classical phenotypical markers used for the identification of tumoral CLL B cell clones. We found that two patients with progressing CLL showed increased expression of the autophagy protein LC3B, in addition to positive expression of CD38 and ZAP70 and unmutated status of IGHV. Our data suggest that activation of autophagy flux may correlate with CLL progression even before Ibrutinib treatment.
Identifiants
pubmed: 32774323
doi: 10.3389/fendo.2020.00321
pmc: PMC7388238
doi:
Substances chimiques
MAP1LC3A protein, human
0
Microtubule-Associated Proteins
0
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
321Informations de copyright
Copyright © 2020 Arroyo, Rodriguez, Bussi, Manzone-Rodriguez, Sastre, Heller, Stanganelli, Slavutsky and Iribarren.
Références
Leuk Lymphoma. 2019 May;60(5):1299-1303
pubmed: 30407097
Nat Rev Dis Primers. 2017 Jan 19;3:16096
pubmed: 28102226
Mod Pathol. 2010 Jul;23(7):937-50
pubmed: 20473282
Leuk Lymphoma. 2018 May;59(5):1239-1243
pubmed: 28868956
Leukemia. 2017 Oct;31(10):2075-2084
pubmed: 28111464
J Cell Biochem. 2017 Oct;118(10):3341-3348
pubmed: 28295550
Trends Immunol. 2013 Dec;34(12):592-601
pubmed: 23928062
J Clin Invest. 2015 Jan;125(1):42-6
pubmed: 25654549
Blood. 2016 Apr 7;127(14):1752-60
pubmed: 26841802
Hematol Oncol Stem Cell Ther. 2013 Mar;6(1):20-5
pubmed: 23664601
J Clin Invest. 2009 May;119(5):1109-23
pubmed: 19363292
Clin Cancer Res. 2013 Feb 15;19(4):833-44
pubmed: 23258740
Nat Rev Cancer. 2012 Apr 26;12(6):401-10
pubmed: 22534666
Hum Pathol. 2011 Oct;42(10):1459-66
pubmed: 21450329
Leuk Res. 2018 Mar;66:8-14
pubmed: 29346066
Lancet. 2010 Oct 2;376(9747):1164-74
pubmed: 20888994
Leuk Res. 2015 Jun;39(6):555-60
pubmed: 25840748
Int Immunopharmacol. 2014 Jan;18(1):55-65
pubmed: 24262302
Br J Haematol. 2016 Apr;173(1):105-13
pubmed: 26848054
Blood. 2014 Jul 3;124(1):49-62
pubmed: 24797299
Cancer Lett. 2019 Feb 1;442:233-241
pubmed: 30419344
Mol Cell. 2010 Oct 22;40(2):280-93
pubmed: 20965422
Blood. 2015 Jul 23;126(4):454-62
pubmed: 26065657
Acta Haematol. 2015;134(1):17-24
pubmed: 25871810
Cancer Res. 2010 May 1;70(9):3431-4
pubmed: 20424122
Blood. 2007 Jun 1;109(11):4679-85
pubmed: 17299097
Semin Cancer Biol. 2013 Oct;23(5):344-51
pubmed: 23774296
J Clin Invest. 2016 Jan;126(1):181-94
pubmed: 26619119
Nat Rev Cancer. 2017 Sep;17(9):528-542
pubmed: 28751651
PLoS One. 2012;7(10):e47357
pubmed: 23091617
Mayo Clin Proc. 2018 May;93(5):651-664
pubmed: 29728204
J Biol Chem. 2008 Jul 11;283(28):19665-77
pubmed: 18375389
Nat Rev Cancer. 2007 Dec;7(12):961-7
pubmed: 17972889
Blood. 2011 Sep 29;118(13):3470-8
pubmed: 21765022